Thao P. Dang

1.7k total citations
21 papers, 1.4k citations indexed

About

Thao P. Dang is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Thao P. Dang has authored 21 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 8 papers in Molecular Biology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Thao P. Dang's work include Developmental Biology and Gene Regulation (7 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Lung Cancer Treatments and Mutations (6 papers). Thao P. Dang is often cited by papers focused on Developmental Biology and Gene Regulation (7 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Lung Cancer Treatments and Mutations (6 papers). Thao P. Dang collaborates with scholars based in United States, Spain and Japan. Thao P. Dang's co-authors include David P. Carbone, Adriana González, Nobuhiro Haruki, Keiko Kawaguchi, Sandra J. Olson, Jun Konishi, Pierre P. Massion, Yu Shyr, Alan Sandler and Roy S. Herbst and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Thao P. Dang

21 papers receiving 1.4k citations

Peers

Thao P. Dang
Stephen Leong United States
Joshua C. Curtin United States
Yigong Fu United States
Claus G. Haase Germany
Allison M. Sawyer United States
Marco Gymnopoulos United States
Myoung‐Eun Han South Korea
Cornelia Schindler United States
Carol O’Brien United States
Gissou Azabdaftari United States
Stephen Leong United States
Thao P. Dang
Citations per year, relative to Thao P. Dang Thao P. Dang (= 1×) peers Stephen Leong

Countries citing papers authored by Thao P. Dang

Since Specialization
Citations

This map shows the geographic impact of Thao P. Dang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thao P. Dang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thao P. Dang more than expected).

Fields of papers citing papers by Thao P. Dang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thao P. Dang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thao P. Dang. The network helps show where Thao P. Dang may publish in the future.

Co-authorship network of co-authors of Thao P. Dang

This figure shows the co-authorship network connecting the top 25 collaborators of Thao P. Dang. A scholar is included among the top collaborators of Thao P. Dang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thao P. Dang. Thao P. Dang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ren, Shengxiang, Jifeng Feng, Shenglin Ma, et al.. (2023). KEYNOTE‐033: Randomized phase 3 study of pembrolizumab vs docetaxel in previously treated, PD‐L1‐positive, advanced NSCLC. International Journal of Cancer. 153(3). 623–634. 12 indexed citations
2.
3.
Schmid, Peter, Javier Cortés, Jonas Bergh, et al.. (2018). KEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo + chemo as neoadjuvant therapy followed by pembro vs placebo as adjuvant therapy for triple-negative breast cancer (TNBC).. Journal of Clinical Oncology. 36(15_suppl). TPS602–TPS602. 27 indexed citations
4.
Schmid, Peter, Yeon Hee Park, Eva Muñoz‐Couselo, et al.. (2017). Pembrolizumab (pembro) + chemotherapy (chemo) as neoadjuvant treatment for triple negative breast cancer (TNBC): Preliminary results from KEYNOTE-173.. Journal of Clinical Oncology. 35(15_suppl). 556–556. 68 indexed citations
5.
Winer, Eric P., Thao P. Dang, Vassiliki Karantza, & Shu‐Chih Su. (2016). KEYNOTE-119: A randomized phase III study of single-agent pembrolizumab (MK-3475) vs single-agent chemotherapy per physician's choice for metastatic triple-negative breast cancer (mTNBC).. Journal of Clinical Oncology. 34(15_suppl). TPS1102–TPS1102. 18 indexed citations
6.
Dang, Thao P., et al.. (2013). Manic fringe inhibits tumor growth by suppressing Notch3 degradation in lung cancer.. PubMed. 3(5). 490–9. 15 indexed citations
7.
Dang, Thao P.. (2012). Notch, Apoptosis and Cancer. Advances in experimental medicine and biology. 727. 199–209. 71 indexed citations
8.
Vo, Kevin D., et al.. (2011). Targeting notch pathway enhances rapamycin antitumor activity in pancreas cancers through PTEN phosphorylation. Molecular Cancer. 10(1). 138–138. 53 indexed citations
9.
Lin, Luping, et al.. (2010). Targeting Specific Regions of the Notch3 Ligand-Binding Domain Induces Apoptosis and Inhibits Tumor Growth in Lung Cancer. Cancer Research. 70(2). 632–638. 55 indexed citations
10.
Chen, Heidi, Shuo Chen, Roy S. Herbst, et al.. (2009). Classification by Mass Spectrometry Can Accurately and Reliably Predict Outcome in Patients with Non-small Cell Lung Cancer Treated with Erlotinib-Containing Regimen. Journal of Thoracic Oncology. 4(6). 689–696. 23 indexed citations
11.
Carbone, David P., Dean Billheimer, Heidi Chen, et al.. (2009). VeriStrat® classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab. Lung Cancer. 69(3). 337–340. 45 indexed citations
12.
Herbst, Roy S., Angela M. Davies, Ronald B. Natale, et al.. (2007). Efficacy and Safety of Single-Agent Pertuzumab, a Human Epidermal Receptor Dimerization Inhibitor, in Patients with Non–Small Cell Lung Cancer. Clinical Cancer Research. 13(20). 6175–6181. 79 indexed citations
13.
Konishi, Jun, Keiko Kawaguchi, Nobuhiro Haruki, et al.. (2007). γ-Secretase Inhibitor Prevents Notch3 Activation and Reduces Proliferation in Human Lung Cancers. Cancer Research. 67(17). 8051–8057. 220 indexed citations
14.
Csiki, Ildiko, Jason D. Morrow, Alan Sandler, et al.. (2005). Targeting Cyclooxygenase-2 in Recurrent Non–Small Cell Lung Cancer: A Phase II Trial of Celecoxib and Docetaxel. Clinical Cancer Research. 11(18). 6634–6640. 91 indexed citations
15.
Haruki, Nobuhiro, Keiko Kawaguchi, Pierre P. Massion, et al.. (2005). Dominant-Negative Notch3 Receptor Inhibits Mitogen-Activated Protein Kinase Pathway and the Growth of Human Lung Cancers. Cancer Research. 65(9). 3555–3561. 133 indexed citations
16.
Kravtsov, Dmitri V., Wenman Wu, Joost C.M. Meijers, et al.. (2004). Dominant factor XI deficiency caused by mutations in the factor XI catalytic domain. Blood. 104(1). 128–134. 71 indexed citations
17.
Dang, Thao P., et al.. (2003). Constitutive activation of Notch3 inhibits terminal epithelial differentiation in lungs of transgenic mice. Oncogene. 22(13). 1988–1997. 88 indexed citations
18.
Yamagata, Noboru, Yu Shyr, Kiyoshi Yanagisawa, et al.. (2003). A training-testing approach to the molecular classification of resected non-small cell lung cancer.. PubMed. 9(13). 4695–704. 94 indexed citations
19.
Nakanishi, Hajime, Yun Sun, Richard Nakamura, et al.. (1997). Positive Correlations Between Cerebral Protein Synthesis Rates and Deep Sleep in Macaca mulatta. European Journal of Neuroscience. 9(2). 271–279. 120 indexed citations
20.
Dang, Thao P., et al.. (1980). Chromosomal abnormalities associated with infertility.. PubMed. 55(4). 469–75. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Stephen Leong Breakdown of academic impact, for papers by Joshua C. Curtin Breakdown of academic impact, for papers by Yigong Fu Breakdown of academic impact, for papers by Claus G. Haase Breakdown of academic impact, for papers by Allison M. Sawyer Breakdown of academic impact, for papers by Marco Gymnopoulos Breakdown of academic impact, for papers by Myoung‐Eun Han Breakdown of academic impact, for papers by Cornelia Schindler Breakdown of academic impact, for papers by Carol O’Brien Breakdown of academic impact, for papers by Gissou Azabdaftari
Rankless by CCL
2026